Skip to main content
    K

    Kyverna Therapeutics, Inc. Common Stock (KYTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.76
    -0.29 (-5.74%)

    Market Cap: $319.27M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kyverna Therapeutics, Inc. Common Stock (KYTX) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Kyverna Therapeutics, Inc. Common Stock (KYTX) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Kyverna Therapeutics, Inc. Common Stock reported EPS of -$0.68, in line with the -$0.68 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    58%(7/12)
    Avg Surprise
    -58.41%

    Upcoming Estimates

    Reports Mar 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.79
    Range-$0.97 - -$0.71
    8 analysts
    Revenue Consensus
    N/A
    RangeN/A
    7 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.80
    Range-$0.90 - -$0.71
    3 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.82+3.2%
    60d ago-$0.800.0%
    30d ago-$0.800.0%
    7d ago-$0.800.0%
    Current-$0.80
    Revenue Consensus
    $500.00K
    RangeN/A
    2 analysts

    Next Report

    KYTX has an expected report date of Mar 24, 2027.

    Earnings History

    Of the 12 quarters below that had an estimate, KYTX beat 7, missed 3 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 731.58% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.68-$0.68-$0.77 - -$0.650.00%In lineN/A53 up, 1 downNov 12, 2026
    Jun 30, 2026-$0.63-$0.67-$0.71 - -$0.62+5.97%BeatN/A53 up, 1 downAug 12, 2026
    Mar 31, 2026-$0.66-$0.73-$0.83 - -$0.62+10.06%BeatN/A54 up, 0 downMay 12, 2026
    Dec 31, 2025-$0.80-$0.86-$1.15 - -$0.64+6.98%BeatN/A52 up, 0 downMar 26, 2026
    Sep 30, 2025-$0.85-$0.95-$0.99 - -$0.86+10.53%BeatN/A51 up, 1 downNov 12, 2025
    Jun 30, 2025-$0.97-$1.04-$1.18 - -$0.87+6.73%BeatN/A52 up, 3 downAug 12, 2025
    Mar 31, 2025-$1.03-$1.00-$1.08 - -$0.87-3.00%MissN/A50 up, 2 downMay 13, 2025
    Dec 31, 2024-$0.87-$0.95N/A+8.65%BeatN/A40 up, 1 downMar 27, 2025
    Sep 30, 2024-$0.80-$0.80-$0.83 - -$0.680.00%In lineN/A52 up, 0 downNov 13, 2024
    Jun 30, 2024-$0.67-$0.68N/A+1.47%BeatN/AN/AN/AAug 12, 2024
    Mar 31, 2024-$1.12-$0.96N/A-16.67%MissN/AN/AN/AMay 14, 2024
    Dec 31, 2023-$26.86-$3.23N/A-731.58%MissN/AN/AN/AFeb 8, 2024
    Last 12 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.65, after -$3.46 the year before. It was -$26.86 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.65N/A
    Dec 31, 2024-$3.46N/A
    Dec 31, 2023-$26.86N/A

    Frequently Asked Questions About KYTX

    When is Kyverna Therapeutics, Inc. Common Stock's next earnings date?

    Kyverna Therapeutics, Inc. Common Stock's next earnings report is expected for Mar 24, 2027.

    Did KYTX beat earnings estimates last quarter?

    Kyverna Therapeutics, Inc. Common Stock reported EPS of -$0.68 for the quarter ended Sep 30, 2026, in line with the -$0.68 estimate.

    What EPS do analysts expect from KYTX next quarter?

    The consensus EPS estimate for Kyverna Therapeutics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.79 from 8 analysts, with estimates from -$0.97 to -$0.71.

    How often does KYTX beat earnings estimates?

    Kyverna Therapeutics, Inc. Common Stock beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +5.74%.